DEFA14A: XWELL Disputes Director Nomination, Cites Deficiencies in CPC Pain & Wellness' Filing

XWELL, Inc. announces that CPC Pain & Wellness' director candidate nomination notice is invalid due to deficiencies and calls for CPC to update its Schedule 13D filing with accurate information.

Summary

• XWELL, Inc. has announced that the director candidate nomination notice submitted by CPC Pain & Wellness SPV, LLC is invalid.
• XWELL claims CPC's notice is deficient and that CPC's Schedule 13D filing lacks specific details about its plans for the company.
• XWELL believes CPC is attempting to gain control of the board to facilitate a transaction involving an underperforming affiliate, which could undervalue XWELL, dilute current stockholders, and benefit CPC at the expense of other stockholders.
• XWELL is urging stockholders to be cautious and question any communications from CPC.
• XWELL intends to file a proxy statement and a WHITE Proxy Card with the SEC in connection with the Company’s 2024 annual meeting of stockholders.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the dispute with CPC, the potential for undervaluation, and the uncertainty surrounding the company's future.

Positives

• XWELL is actively defending itself against what it perceives as a hostile takeover attempt.
• XWELL is providing stockholders with information to make informed decisions.
• XWELL is committed to protecting stockholder value.

Negatives

• CPC's attempt to nominate directors suggests a potential conflict or disagreement regarding the company's direction.
• The invalidation of CPC's nomination notice and the ongoing dispute could create uncertainty for investors.
• XWELL believes CPC's actions could lead to the undervaluation of the company and dilution of stockholder value.

Risks

• The dispute with CPC could escalate and lead to further legal action.
• The potential transaction being pursued by CPC could negatively impact XWELL's stock price and long-term prospects.
• Uncertainty surrounding the company's future direction could deter potential investors.

Future Outlook

XWELL intends to file a proxy statement and a WHITE Proxy Card with the SEC in connection with the Company’s 2024 annual meeting of stockholders.

Management Comments

• XWELL calls on CPC to promptly update its Schedule 13D to transparently inform all of the Company’s stockholders and the broader investing public of its plans and related legal action, which XWELL intends to dispute vigorously.

Industry Context

This announcement highlights the increasing activism and scrutiny companies face from investors, particularly regarding corporate governance and strategic direction. It's not uncommon for companies to face challenges from activist investors seeking to influence company strategy or board composition.

Comparison to Industry Standards

• It is common for companies to defend themselves against perceived hostile takeovers.
• The actions taken by XWELL are similar to those taken by other companies in similar situations.
• The company is following standard procedures for communicating with shareholders and the SEC.

Legal Proceedings

• CPC has filed litigation against XWELL in an apparent attempt to advance its own objectives.
• XWELL intends to dispute the legal action vigorously.

Stakeholder Impact

• Shareholders are advised to be cautious and question communications from CPC.
• The dispute could impact employee morale and productivity.
• The potential transaction being pursued by CPC could affect the company's relationships with customers and suppliers.

Next Steps

• XWELL will file a proxy statement and a WHITE Proxy Card with the SEC.
• XWELL intends to dispute CPC's legal action vigorously.
• Stockholders are encouraged to read the proxy statement and other documents filed with the SEC carefully.

Key Dates

Keywords

XWELL, CPC Pain & Wellness, Proxy Fight, Director Nomination, Schedule 13D, Corporate Governance, Stockholders, Takeover, Board of Directors